The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or...read more
Allogene Therapeutics, a Phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, raised $288 million by offering 16 million shares at $18, the high end of the range of $16 to $18. Allogene Therapeutics plans to list on the Nasdaq under the symbol...read more
ThiS 5-IPO week is led by cloud-based business planning software provider Anaplan, which hopes to follow in the footsteps of the many other high-flying SaaS IPOs of 2018 (31% average return). Also pricing this week is Livent, which produces lithium...read more
Allogene Therapeutics, a phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $272 million by offering 16 million shares at a price range of...read more
US IPO Weekly Recap: Despite sell-off, 4 IPOs price with unicorn Anaplan up 43%
The markets roiled and recent IPOs took a nosedive, but four deals managed to raise $1.0 billion this week. Software unicorn Anaplan (PLAN) and cancer biotech Allogene (ALLO) popped over 40%. Two others ended at or...read more
Allogene Therapeutics prices IPO at $18, the high end of the range
Allogene Therapeutics, a Phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, raised $288 million by offering 16 million shares at $18, the high end of the range of $16 to $18. Allogene Therapeutics plans to list on the Nasdaq under the symbol...read more
US IPO Week Ahead: Anaplan leads this upcoming 5-IPO week
ThiS 5-IPO week is led by cloud-based business planning software provider Anaplan, which hopes to follow in the footsteps of the many other high-flying SaaS IPOs of 2018 (31% average return). Also pricing this week is Livent, which produces lithium...read more
CAR T cell therapy biotech Allogene Therapeutics sets terms for $272 million IPO
Allogene Therapeutics, a phase 1 biotech developing off-the-shelf CAR T cell cancer therapies, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $272 million by offering 16 million shares at a price range of...read more